Shanghai Hile Bio-Technology Co., Ltd.

603718

CNE1000022T4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-12 EDT			5-day change	1st Jan Change
8.31 ^CNY	-3.48%		-1.89%	-22.41%

04-29	Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-29	Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shanghai Hile Bio-Technology Plans to Sell Biological Products Unit

April 11, 2023 at 04:17 am

Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) said it plans to sell biological products unit for CNY 113.3 million ($16.45 million).

Latest news about Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Shanghai Hile Bio-Technology Co., Ltd.(XSSC:603718) added to S&P Global BMI Index	23-09-18	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Shanghai Zhizhuo Enterprise Management Consulting Co., Ltd. agreed to acquire Shanghai Caiyin Biotechnology Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for CNY 2 million.	23-04-11	CI
Shandong Sinder Technology Co., Ltd agreed to acquire Shandong Hile Biological Products Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for approximately CNY 110 million.	23-04-11	CI
Shanghai Hile Bio-Technology Plans to Sell Biological Products Unit	23-04-11	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-11	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Shandong Hile Biological Products Co., Ltd. announced that it has received CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	22-09-29	CI
Shandong Hile Biological Products Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	22-08-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
WuXi Vaccines Inc. announced that it expects to receive $136 million in funding from Shanghai Hile Bio-Technology Co., Ltd., WuXi Biologics Inc.	21-05-12	CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it has received CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	21-04-28	CI
Shanghai Hile Bio-Technology Co., Ltd. completed the acquisition of 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A.	21-04-28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-23	CI
WuXi Biologics Cayman : , Shanghai Hile to Restructure Vaccine JV	21-04-02	MT
Shanghai Hile Bio-Technology Co., Ltd. intends to acquire 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A. for CNY 56 million.	21-03-16	CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it expects to receive CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	21-03-14	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-27	CI

Chart Shanghai Hile Bio-Technology Co., Ltd.

Duration

Period

Chart Shanghai Hile Bio-Technology Co., Ltd.

More charts

SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Companyâs products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndromeâ76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD.	-22.41%	756M
ZOETIS INC.	-14.93%	76.62B
BLUESTAR ADISSEO COMPANY	+26.62%	3.76B
VIRBAC	+0.14%	3.24B
VIMIAN GROUP AB	+18.58%	1.65B
JINYU BIO-TECHNOLOGY CO., LTD.	-7.99%	1.53B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-22.43%	1.3B
VETOQUINOL SA	-4.10%	1.25B
WUHAN KEQIAN BIOLOGY CO.,LTD	-9.08%	1.19B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	+5.25%	1.1B

Veterinary Drugs

Shanghai Hile Bio-Technology Co., Ltd.

Equities

603718

CNE1000022T4

Pharmaceuticals

Shanghai Hile Bio-Technology Plans to Sell Biological Products Unit

Latest news about Shanghai Hile Bio-Technology Co., Ltd.

Chart Shanghai Hile Bio-Technology Co., Ltd.

Company Profile

Income Statement Evolution

Sector Veterinary Drugs